teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. headquartered in wayne, pa, teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
Company profile
Ticker
TFX
Exchange
Website
CEO
Liam Kelly
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
1902 Federal Road, LLC • Arrow Internacional de Chihuahua, S.A. de C.V. • Arrow Internacional de Mexico, S.A. de C.V. • Arrow International • Arrow International LLC • Arrow Interventional, Inc. • Distribuidora Arrow, S.A. de C.V. • Essential Medical LLC • Hudson Respiratory Care Tecate, S. de R.L. de C.V. • ICOR AB ...
IRS number
231147939
TFX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
5 Apr 24
DEF 14A
Definitive proxy
1 Apr 24
10-K
2023 FY
Annual report
23 Feb 24
8-K
Teleflex Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 24
S-8
Registration of securities for employees
3 Nov 23
10-Q
2023 Q3
Quarterly report
3 Nov 23
8-K
Teleflex Reports Third Quarter Financial Results and Full Year 2023 Outlook
2 Nov 23
8-K
Other Events
31 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Teleflex Reports Second Quarter Financial Results and Full Year 2023 Outlook
3 Aug 23
Transcripts
TFX
Earnings call transcript
2023 Q4
22 Feb 24
TFX
Earnings call transcript
2023 Q3
2 Nov 23
TFX
Earnings call transcript
2023 Q2
3 Aug 23
TFX
Earnings call transcript
2023 Q1
4 May 23
TFX
Earnings call transcript
2023 Q1
4 May 23
TFX
Earnings call transcript
2022 Q4
23 Feb 23
TFX
Earnings call transcript
2022 Q3
27 Oct 22
TFX
Earnings call transcript
2022 Q2
28 Jul 22
TFX
Earnings call transcript
2022 Q1
28 Apr 22
TFX
Earnings call transcript
2021 Q4
24 Feb 22
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
94.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 466 |
Opened positions | 58 |
Closed positions | 55 |
Increased positions | 152 |
Reduced positions | 175 |
13F shares | Current |
---|---|
Total value | 8.76 tn |
Total shares | 44.66 mm |
Total puts | 36.21 k |
Total calls | 41.20 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
T. Rowe Price Investment Management | 7.10 mm | $1.39 tn |
Vanguard | 5.40 mm | $1.06 tn |
JHG Janus Henderson | 4.21 mm | $827.43 bn |
BLK Blackrock | 4.07 mm | $799.57 bn |
MS Morgan Stanley | 2.82 mm | $553.99 bn |
Wellington Management | 2.44 mm | $480.03 bn |
STT State Street | 2.28 mm | $448.46 bn |
T. Rowe Price | 1.97 mm | $387.07 bn |
Geode Capital Management | 1.01 mm | $198.28 bn |
Cooke & Bieler | 695.66 k | $136.63 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Mar 24 | Cameron P Hicks | Common Stock | Sell | Dispose S | No | No | 225 | 7,401 | 1.67 mm | 10,050.034 |
5 Mar 24 | Cameron P Hicks | Common Stock | Option exercise | Acquire M | No | No | 144.79 | 4,400 | 637.08 k | 17,451.034 |
5 Mar 24 | Cameron P Hicks | Common Stock | Option exercise | Acquire M | No | No | 121 | 3,001 | 363.12 k | 13,051.034 |
5 Mar 24 | Cameron P Hicks | Stock Option / Common Stock | Option exercise | Dispose M | No | No | 144.79 | 4,400 | 637.08 k | 6,599 |
5 Mar 24 | Cameron P Hicks | Stock Option / Common Stock | Option exercise | Dispose M | No | No | 121 | 3,001 | 363.12 k | 0 |
2 Mar 24 | James Winters | Common Stock | Payment of exercise | Dispose F | No | No | 223 | 305 | 68.02 k | 3,395 |
2 Mar 24 | Thomas E Powell | Common Stock | Payment of exercise | Dispose F | No | No | 223 | 810 | 180.63 k | 16,615 |
2 Mar 24 | Jay White | Common Stock | Payment of exercise | Dispose F | No | No | 223 | 239 | 53.30 k | 5,960 |
2 Mar 24 | Liam Kelly | Common Stock | Payment of exercise | Dispose F | No | No | 223 | 1,840 | 410.32 k | 26,984.092 |
2 Mar 24 | Cameron P Hicks | Common Stock | Payment of exercise | Dispose F | No | No | 225 | 216 | 48.60 k | 10,050.034 |
News
(TFX) - Analyzing Teleflex's Short Interest
15 Apr 24
Teleflex: Dividend Insights
26 Feb 24
JMP Securities Reiterates Market Outperform on Teleflex, Maintains $285 Price Target
23 Feb 24
RBC Capital Maintains Outperform on Teleflex, Lowers Price Target to $265
23 Feb 24
Breaking Down Teleflex: 4 Analysts Share Their Views
23 Feb 24
Press releases
Teleflex Announces First Quarter 2024 Earnings Conference Call Information
18 Apr 24
Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types
2 Apr 24
Teleflex's Climate Targets Validated by the Science Based Targets Initiative
28 Mar 24
Teleflex Announces Quarterly Dividend
22 Feb 24
Teleflex Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 24